Cagrilintide vs Petrelintide: What the Research Compares

Cagrilintide and petrelintide are investigational medicines in clinical trials. Both are long-acting amylin receptor agonists studied for obesity and related cardiometabolic conditions, and reviews published in 2026 describe them within the emerging amylin analog class rather than as marketed products (PMID 42452898, PMID 41747885). This page is for educational purposes only and is not medical advice; consult a licensed physician about any medicine, including whether a clinical trial or an approved therapy is appropriate for a given person.

Is There a Head-to-Head Trial?

No published randomized trial directly comparing cagrilintide with petrelintide appears in the verified literature summarised here. The 2026 reviews of amylin analogs describe the two agents in parallel as separate development programs with separate trial sets, and they do not report a shared randomized comparison with common arms and a common primary endpoint (PMID 42452898, PMID 42586227). Because no head-to-head data exist in that citation set, any comparison between the two rests on indirect reading across trials that enrolled different populations, used different comparators and measured outcomes over different durations.

Indirect comparison has well known limits. Differences in baseline body weight, background therapy, run-in procedures, dose escalation schedules and trial length can all move a weight or glycemic endpoint independently of the molecule being tested. The reviews that cover both compounds present them as members of one pharmacological class under active investigation rather than ranking them against each other (PMID 41747885).

Shared Class and Mechanism

Amylin is a pancreatic beta cell hormone co-secreted with insulin that acts on receptors in the hindbrain to influence satiation, gastric emptying and glucagon secretion. Reviews of the class reported that native amylin aggregates readily and has a short half-life, so medicinal chemistry efforts produced analogs engineered for solubility and extended duration, which is the structural basis for the long-acting agents now in trials (PMID 41747885). The 2026 review in Diabetes, Obesity and Metabolism characterised amylin analogs as a next major class of weight loss therapy and summarised experimental data together with early-phase clinical trials (PMID 42452898).

Both cagrilintide and petrelintide fall inside this description. A 2026 review in Pharmacological Research framed amylin-based pharmacotherapy as part of a search for better tolerated weight loss drugs beyond GLP-1 receptor agonists, and reported that amylin receptor agonism acts through satiation signalling pathways that overlap with but are distinguishable from incretin signalling (PMID 42586227).

Where the Programs Differ in Framing

Published reviews describe cagrilintide largely in two contexts: as a single agent amylin analog and as a fixed combination partner with the GLP-1 receptor agonist semaglutide, a coformulation that reviews discuss as a dual-mechanism approach to weight reduction (PMID 42452898). Petrelintide is described in the same reviews as a long-acting amylin analog advanced primarily as monotherapy within the broader set of amylin-related peptides under development (PMID 41747885). That difference in program design is one reason direct comparison is difficult: a combination product and a single-agent product answer different clinical questions.

Side-by-Side Summary of the Separate Evidence Bases

The table restates what the cited reviews contain. Specific trial names, enrolled sample sizes, dose escalation steps and percentage weight change figures for individual studies are not reproduced here because the verified citation set for this page consists of narrative and systematic reviews of the class rather than individual trial reports, and inventing those details would misstate the record (PMID 42586227).

Regulatory Status

Both compounds are described in the 2026 literature as investigational agents progressing through clinical trials for obesity and type 2 diabetes, which means their safety and efficacy are still being characterised by regulators rather than settled (PMID 42452898). Reviews of long-acting amylin-related peptides placed them among a group of molecules under active development alongside other amylin and dual-mechanism candidates (PMID 41747885). Availability, labelling and permitted use are determined by national regulators and by the prescribing clinician responsible for an individual patient, and questions about access belong in that conversation.

One approved amylin analog already exists as historical context for the class. Reviews noted that earlier amylin pharmacology established proof of concept for satiation-directed therapy, and that the newer long-acting molecules were designed to address the pharmacokinetic and formulation limits of that first generation (PMID 41747885).

Adverse Events: What Studies Report

Across the amylin analog class, reviewers reported that gastrointestinal effects dominated the adverse event profile in clinical trials, with nausea and vomiting the most frequently described events (PMID 42452898). The 2026 Pharmacological Research review discussed amylin-based pharmacotherapy specifically in the context of searching for better tolerated weight loss options and reported that tolerability profiles were a central consideration in how these programs were designed and evaluated (PMID 42586227).

Reviewers of long-acting amylin-related peptides likewise reported that adverse events were predominantly gastrointestinal and that dose escalation schedules were used in trials to manage them (PMID 41747885). Because the published head-to-head comparison between cagrilintide and petrelintide does not exist in this citation set, no statement can be made about which agent produced fewer events; event rates measured in different trials with different populations and escalation protocols are not interchangeable (PMID 42586227).

Injection site reactions, appetite suppression severe enough to affect intake, and effects related to delayed gastric emptying are described in the general pharmacology of amylin receptor agonism summarised by reviewers (PMID 41747885). Anyone evaluating these risks for a personal situation should raise them with a licensed physician, who can weigh them against medical history and concurrent medicines.

How to Read Comparisons Between These Two Agents

• Check whether a comparison is direct or indirect. The reviews cited here present cagrilintide and petrelintide side by side as class members, not as randomized comparators (PMID 42452898).
• Check the population. Trials enrolling participants with type 2 diabetes generally report different weight outcomes than trials enrolling participants without diabetes, a point reviewers made when summarising amylin trial data (PMID 42586227).
• Check whether the agent was tested alone or in combination. Reviews described cagrilintide in both single-agent and combination contexts, which changes what an endpoint means (PMID 42452898).
• Check trial duration. Weight trajectories in the amylin literature were reported over differing follow-up windows, so comparing endpoints taken at different times is unreliable (PMID 41747885).
• Check whether a figure comes from a trial report or from a review summary. Review articles condense and may round or contextualise primary results (PMID 42586227).

Open Questions in the Published Literature

Reviewers identified several unresolved issues for the amylin class as a whole. These included the durability of weight reduction after treatment stops, the composition of weight lost in terms of fat and lean mass, long-term cardiovascular and metabolic outcomes, and whether amylin agonism combined with incretin agonism delivers additive or complementary effects on tolerability as well as efficacy (PMID 42452898, PMID 42586227). Reviews of long-acting amylin-related peptides also noted that comparative positioning within the class will depend on larger and longer trials that have not yet reported in the summarised record (PMID 41747885).

Until such data are published, descriptions of either agent as superior to the other go beyond what the literature supports. The accurate summary is that two investigational long-acting amylin receptor agonists are being studied in overlapping indications, that their reported adverse events are predominantly gastrointestinal, and that no direct randomized comparison between them is available in the reviews cited on this page (PMID 42586227).

References

• Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early-Phase Clinical Trials (Diabetes, Obesity and Metabolism, 2026)
• Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes (Peptides, 2026)
• Beyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs (Pharmacological Research, 2026)